Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Drug Alcohol Depend ; 206: 107743, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31801107

RESUMEN

BACKGROUND: Given the rising incidence of opioid overdose in the United States, naloxone access is critical for high-risk populations, such as persons who inject drugs (PWID). Yet not all PWID have access to this life-saving antidote. With PWID in Michigan recruited via respondent driven sampling in 2017, after the 2016 standing order expanding naloxone availability through local pharmacies, we explored possible access disparities. METHODS: With 46 seeds recruited from agencies serving local PWID communities, we obtained a sample of N = 410 PWID from Southeast Michigan (n = 285 form urban Detroit, and 125 for suburban/rural areas outside Detroit). Participants completed questionnaires detailing socio-demographics, health history, substance use and treatment access, including naloxone. We used multiple logistic regression to examine the predictors of self-reported naloxone access based on participant characteristics (e.g., demographics, health status) and geography (urban vs. suburban/rural). RESULTS: Self-reported naloxone access differed significantly by location (urban = 18.3 %; suburban/rural = 41.9 %). In multivariable analyses, naloxone access was significantly associated with race, household income, employment, health insurance, recent homelessness, prescription opioid usage, Hepatitis A and C status, Hepatitis A vaccination, Hepatitis C testing, access to drug treatment and services, and hospital as the usual place of care. CONCLUSION: Despite recent policies to expand access, our results indicate that naloxone access among high-risk PWID is low. This warrants future research to identify effective channels to reduce barriers and increase naloxone access.


Asunto(s)
Accesibilidad a los Servicios de Salud , Disparidades en Atención de Salud , Personas con Mala Vivienda , Naloxona/administración & dosificación , Abuso de Sustancias por Vía Intravenosa/tratamiento farmacológico , Abuso de Sustancias por Vía Intravenosa/epidemiología , Adulto , Estudios Transversales , Femenino , Accesibilidad a los Servicios de Salud/economía , Disparidades en Atención de Salud/economía , Hepatitis C/dietoterapia , Hepatitis C/economía , Hepatitis C/epidemiología , Humanos , Masculino , Michigan/epidemiología , Persona de Mediana Edad , Naloxona/economía , Trastornos Relacionados con Opioides/dietoterapia , Trastornos Relacionados con Opioides/economía , Trastornos Relacionados con Opioides/epidemiología , Factores de Riesgo , Autoinforme , Abuso de Sustancias por Vía Intravenosa/economía , Encuestas y Cuestionarios
2.
Food Chem ; 274: 900-906, 2019 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-30373026

RESUMEN

Detarium microcarpum is a plant indigenous to Africa, which occurs naturally in many African countries, particularly in savannah regions. Its leaves and fruits are used mainly as food and as folk medicine. It has anti-diabetic, antioxidant, and hepatitis C inhibitor properties and has been traditionally utilised in cancer treatment. This review examines published work on the nutritional, pharmacological, and traditional uses of Detarium microcarpum. This plant may become valuable if the fruit, stems, roots, and leaves are extracted for nutraceutical purposes.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Antioxidantes/farmacología , Fabaceae/química , Fabaceae/fisiología , Hipoglucemiantes/farmacología , África , Antineoplásicos Fitogénicos/química , Antioxidantes/química , Inhibidores de la Colinesterasa/química , Inhibidores de la Colinesterasa/farmacología , Frutas/química , Hepatitis C/dietoterapia , Humanos , Hipoglucemiantes/química , Medicinas Tradicionales Africanas , Valor Nutritivo , Extractos Vegetales/farmacología , Gomas de Plantas/química , Hojas de la Planta/química , Raíces de Plantas/química , Eliminación de Residuos Líquidos/métodos
3.
J Clin Gastroenterol ; 52(1): 55-59, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28617761

RESUMEN

BACKGROUND: Hepatitis C virus (HCV) is a global medical health concern. Egypt has the highest HCV prevalence. Few studies have assessed the HCV prevalence rates among Egyptian-born expatriates. We sought to define the HCV prevalence Egyptian-born individuals residing in the Southern California area. PATIENTS AND METHODS: We screened Egyptian-born individuals in houses of worship in the Southern California area using a point of care test HCV antibody test. Results were confirmed by testing the blood for viral load. Demographic information including risk factors were also collected. Individuals were contacted with their results, and those found to be detectable HCV antibodies were referred for further testing and additional care. RESULTS: Three hundred twenty-six Egyptian expatriates from 7 houses of worship in Southern California were screened for the HCV infection. Most of the participants were screened at Coptic Churches. Nine of these individuals were found to be HCV infected (2.8%). We found an increased HCV seroprevalence in subjects were male and born in Egyptian urban areas. Five of the 9 subjects (56%) who tested positive were not baby boomers and only 2 of these 9 subjects (22%) had recognized Center for Disease Control risk factors. CONCLUSIONS: The HCV prevalence rate of Egyptian-born individuals living in the Southern California area was lower compared with the prevalence rate in the general Egyptian population, but higher than that seen in the general US population. The utility of using Center for Disease Control risk factors to define individuals at risk of HCV among Egyptian expatriates is not applicable.


Asunto(s)
Hepacivirus/inmunología , Hepatitis C/epidemiología , California/epidemiología , Egipto/etnología , Femenino , Hepatitis C/sangre , Hepatitis C/dietoterapia , Hepatitis C/prevención & control , Anticuerpos contra la Hepatitis C/sangre , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Seroepidemiológicos
4.
Liver Int ; 35(4): 1303-14, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25156780

RESUMEN

BACKGROUND & AIMS: Branched-chain amino acids (BCAA) reduce the incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the mechanisms that underlie these effects remain unknown. Previously, we reported that oxidative stress in male transgenic mice that expressed hepatitis C virus polyprotein (HCVTgM) caused hepatic iron accumulation by reducing hepcidin transcription, thereby leading to HCC development. This study investigated whether long-term treatment with BCAA reduced hepatic iron accumulation and oxidative stress in iron-overloaded HCVTgM and in patients with HCV-related advanced fibrosis. METHODS: Male HCVTgM were fed an excess-iron diet that comprised either casein or 3.0% BCAA, or a control diet, for 6 months. RESULTS: For HCVTgM, BCAA supplementation increased the serum hepcidin-25 levels and antioxidant status [ratio of biological antioxidant potential (BAP) relative to derivatives of reactive oxygen metabolites (dROM)], decreased the hepatic iron contents, attenuated reactive oxygen species generation, and restored mitochondrial superoxide dismutase expression and mitochondrial complex I activity in the liver compared with mice fed the control diet. After 48 weeks of BCAA supplementation in patients with HCV-related advanced fibrosis, BAP/dROM and serum hepcidin-25 increased and serum ferritin decreased compared with the pretreatment levels. CONCLUSIONS: BCAA supplementation reduced oxidative stress by restoring mitochondrial function and improved iron metabolism by increasing hepcidin-25 in both iron-overloaded HCVTgM and patients with HCV-related advanced fibrosis. These activities of BCAA may partially account for their inhibitory effects on HCC development in cirrhosis patients.


Asunto(s)
Aminoácidos de Cadena Ramificada/administración & dosificación , Proteínas en la Dieta/administración & dosificación , Hepacivirus/metabolismo , Hepatitis C/dietoterapia , Hierro/metabolismo , Cirrosis Hepática/dietoterapia , Hígado/metabolismo , Estrés Oxidativo , Poliproteínas/metabolismo , Proteínas Virales/metabolismo , Anciano , Anciano de 80 o más Años , Animales , Antioxidantes/metabolismo , Biomarcadores/sangre , Modelos Animales de Enfermedad , Femenino , Ferritinas/sangre , Hepacivirus/genética , Hepatitis C/sangre , Hepatitis C/genética , Hepatitis C/metabolismo , Hepcidinas/sangre , Humanos , Japón , Cirrosis Hepática/sangre , Cirrosis Hepática/genética , Cirrosis Hepática/metabolismo , Masculino , Ratones Transgénicos , Poliproteínas/genética , Especies Reactivas de Oxígeno/sangre , Factores de Tiempo , Resultado del Tratamiento , Proteínas Virales/genética
5.
Biol Trace Elem Res ; 152(2): 187-94, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23412808

RESUMEN

The use of natural remedies and pharmacological mineral supplements for liver disease treatment has a long history. In present study, the levels of selenium (Se) and zinc (Zn) were determined in biological samples (serum and whole blood) of female hepatitis C patients (n = 132), age ranged 30-45 years, before and after 30 days treatment with herbal/pharmaceutical supplements. For comparative study, 128 age-matched female subjects, residing in the same residential areas and have socioeconomic status, were selected as referents. The Se and Zn in supplements, blood, and sera were determined by atomic absorption spectrometry. It was observed that Zn and Se in blood and serum samples of viral hepatitis C (HCV) patients were reduced in the range of 28.6-39 % and 24-36 %, respectively, as compared to those of referents. After herbal/pharmaceutical supplementations, 20.6-25.0 and 9.15-13.2 % of Zn and 10.6-12.1 and 19.6-21.4 % of Se were enhanced in sera and blood samples of HCV patients, respectively. The resulted data indicated that the levels of Se and Zn in addition to some biochemical parameters were improved in HCV patients after herbal/pharmaceutical supplementation. The effects of both supplements were not significantly different (p > 0.05).


Asunto(s)
Hepatitis C/sangre , Selenio/sangre , Zinc/sangre , Adulto , Suplementos Dietéticos , Femenino , Hepatitis C/dietoterapia , Hepatitis C/tratamiento farmacológico , Humanos , Persona de Mediana Edad , Oligoelementos/sangre
6.
Int J Cancer ; 115(2): 290-5, 2005 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-15688396

RESUMEN

To determine if the risk of hepatocellular carcinoma (HCC) is reduced by consumption of soya foods, we conducted a case-control study within a cohort of Japanese A-bomb survivors. We compared the prediagnosis consumption of isoflavone-rich miso soup and tofu to HCC risk, adjusting for hepatitis B (HBV) and C (HCV) viral infections, the major HCC risk factors in this population. The study included 176 pathologist-confirmed cases of HCC diagnosed in 1964-1988 and 560 controls who died of diseases other than liver cancer. We examined dietary information collected at least 2 years before diagnosis or death and tissue-based measures of viral hepatitis. Using logistic regression, crude ORs were 0.5 (95% CI 0.29-0.95) and 0.5 (95% CI 0.20-0.99) for high vs. low miso soup and tofu intake, respectively. Adjusting for year of birth, sex, HBV, HCV and other factors, the OR for miso soup was unchanged at 0.5 (95% CI 0.14-1.55), and miso results were similar when ORs were recalculated separately for earlier and later birth cohorts to assess consistency of results. The adjusted OR for tofu was 0.9 (95% CI 0.20-3.51). We also found a statistically significant (p < 0.0001) interaction between sex and HCV, with risk of HCC being substantially higher for women. We conclude that consumption of miso soup and other soya foods may reduce HCC risk.


Asunto(s)
Carcinoma Hepatocelular/dietoterapia , Hepatitis B/dietoterapia , Hepatitis C/dietoterapia , Neoplasias Hepáticas/dietoterapia , Alimentos de Soja , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/etiología , Estudios de Casos y Controles , Estudios de Cohortes , Conducta Alimentaria , Hepacivirus/aislamiento & purificación , Hepatitis B/complicaciones , Hepatitis B/epidemiología , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis C/complicaciones , Hepatitis C/epidemiología , Humanos , Japón , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/etiología , Factores de Riesgo
7.
Antiviral Res ; 63 Suppl 1: S11-8, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15450381

RESUMEN

Surrogate markers are an important component in the process of investigating management and prevention strategies, and for increasing understanding of viral diseases. The importance of surrogate markers and applied statistical models is particularly true for HIV. For HIV infection, the development of such methods provides new approaches for evaluation of HIV therapies and vaccines, and for the study of HIV transmission and its pathogenesis. The complex natural history of hepatitis B infection demonstrates that viral load is not the only predictor of transmission of this virus; for hepatitis C infection, viral load per se is not a prognostic factor for disease progression, but cumulative viral load may affect the outcome, and therapy is aimed at eliminating active viral replication.


Asunto(s)
Infecciones por VIH/transmisión , VIH/fisiología , Hepacivirus/fisiología , Virus de la Hepatitis B/fisiología , Hepatitis B/transmisión , Hepatitis C/transmisión , Biomarcadores , Recuento de Linfocito CD4 , Transmisión de Enfermedad Infecciosa/prevención & control , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Hepatitis B/tratamiento farmacológico , Hepatitis B/epidemiología , Hepatitis B/virología , Hepatitis C/dietoterapia , Hepatitis C/epidemiología , Hepatitis C/prevención & control , Hepatitis C/virología , Humanos , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Carga Viral , Replicación Viral
8.
J Coll Physicians Surg Pak ; 13(8): 477-82, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12921690

RESUMEN

Hepatitis-C is a silent epidemic. Proper measures are required to be reinforced to prevent the spread of this disease. Combination treatment with interferon and ribavirin has been holding ground in the battle to fight this disease. The number of responders to hepatitis-C has increased even more with the advent of pegylated interferon. The treatment has to be well planned and a pre-treatment evaluation is mandatory. Similarly, during treatment, proper monitoring of the patients is of utmost importance. However, there are treatment limits for each genotype which must be respected. There is no single approach for non-responders, hence, this situation continues to be a therapeutic dilemma. Use of interferon in compensated cirrhosis has its own limitations while its role in decompensated cirrhosis remains experimental only. Liver biopsy has its importance in proper evaluation of the patient. Acute hepatitis-C is rare but current data suggests that active treatment is as much necessary for acute as it is for chronic hepatitis.


Asunto(s)
Antivirales/uso terapéutico , Hepatitis C/dietoterapia , Consejo/métodos , Hepatitis C/terapia , Humanos
9.
Vopr Pitan ; (1): 10-3, 1998.
Artículo en Ruso | MEDLINE | ID: mdl-9606859

RESUMEN

Acid mussel hydrolisate MIGI-K LP is a food product, and a medical and prophylactic preparation containing a full set of irreplaceable amino acids (with the exception of thriptophane), essential fatty acids, macro- and microelements. MIGI-K LP can be used as a foot additive which improves the taste and increases the food qualities of the product, and as a medical preparation against some diseases.


Asunto(s)
Bivalvos/metabolismo , Aditivos Alimentarios/aislamiento & purificación , Depuradores de Radicales Libres/aislamiento & purificación , Hidrolisados de Proteína/aislamiento & purificación , Protectores contra Radiación/aislamiento & purificación , Mariscos , Adolescente , Adulto , Anciano , Aminoácidos/análisis , Animales , Niño , Preescolar , Ácidos Grasos/análisis , Enfermedades Gastrointestinales/dietoterapia , Hepatitis B/dietoterapia , Hepatitis C/dietoterapia , Humanos , Lactante , Persona de Mediana Edad , Control de Calidad , Oligoelementos/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...